- Home
- ICCC vs ONCY Comparison
ICCC vs ONCY Comparison
Compare ICCC & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- ONCY
- Stock Information
- Founded
- ICCC 1982
- ONCY 1998
- Country
- ICCC United States
- ONCY Canada
- Employees
- ICCC N/A
- ONCY N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- ONCY Pharmaceuticals and Biotechnology
- Sector
- ICCC Health Care
- ONCY Health Care
- Exchange
- ICCC Nasdaq
- ONCY Nasdaq
- Market Cap
- ICCC 48.3M
- ONCY 49.2M
- IPO Year
- ICCC 1987
- ONCY 1999
- Fundamental
- Price
- ICCC $5.50
- ONCY $0.56
- Analyst Decision
- ICCC
- ONCY Strong Buy
- Analyst Count
- ICCC 0
- ONCY 3
- Target Price
- ICCC N/A
- ONCY $4.33
- AVG Volume (30 Days)
- ICCC 39.3K
- ONCY 330.3K
- Earning Date
- ICCC 05-14-2025
- ONCY 05-08-2025
- Dividend Yield
- ICCC N/A
- ONCY N/A
- EPS Growth
- ICCC N/A
- ONCY N/A
- EPS
- ICCC N/A
- ONCY N/A
- Revenue
- ICCC $26,493,169.00
- ONCY N/A
- Revenue This Year
- ICCC N/A
- ONCY N/A
- Revenue Next Year
- ICCC N/A
- ONCY N/A
- P/E Ratio
- ICCC N/A
- ONCY N/A
- Revenue Growth
- ICCC 51.63
- ONCY N/A
- 52 Week Low
- ICCC $3.34
- ONCY $0.47
- 52 Week High
- ICCC $5.82
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- ICCC 59.13
- ONCY 45.75
- Support Level
- ICCC $4.63
- ONCY $0.47
- Resistance Level
- ICCC $5.72
- ONCY $0.65
- Average True Range (ATR)
- ICCC 0.42
- ONCY 0.05
- MACD
- ICCC 0.05
- ONCY 0.01
- Stochastic Oscillator
- ICCC 79.82
- ONCY 50.00
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.